New combo therapy targets hard-to-treat colorectal and endometrial tumors
NCT ID NCT06680739
First seen Jun 02, 2026 · Last updated Jun 13, 2026 · Updated 1 time
Summary
This phase 2 study tests two immunotherapy drugs, durvalumab and tremelimumab, alone or together, in 60 people with colorectal or endometrial cancer. It focuses on tumors that are either unstable (MSI) or stable (MSS) to see if the drugs can shrink or control the cancer. The goal is to find better treatment options for these cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Vall d'Hebron Institute of Oncology
RECRUITINGBarcelona, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.